BACKGROUND AND AIM: Our purpose is to study the clinical significance of Fas/FasL expression in colon cancer and liver metastases (LM). MATERIAL AND METHODS: The expression of Fas/FasL in 68 patients with colon cancer was examined immunohistochemically and correlated to the clinicopathological features of the tumors. RESULTS: High expression of FasL, was observed in stage D and in LM (p=0.024). Fas expression was reduced in stage D tumors and in LM, when compared to earlier stages of disease (p=0.024). LM had also shown a decreased expression of Fas (p=0.016). Tumors with low FasL expression upregulate more often their Fas expression (p = 0.028). No correlation could be established regarding the patients survival. CONCLUSIONS: Low expression of Fas and high expression of FasL are more often in colon tumor stage D and in liver metastasis; these imply tumor aggression, resistance against apoptosis, and could be held as negative prognostic factors.
BACKGROUND AND AIM: Our purpose is to study the clinical significance of Fas/FasL expression in colon cancer and liver metastases (LM). MATERIAL AND METHODS: The expression of Fas/FasL in 68 patients with colon cancer was examined immunohistochemically and correlated to the clinicopathological features of the tumors. RESULTS: High expression of FasL, was observed in stage D and in LM (p=0.024). Fas expression was reduced in stage D tumors and in LM, when compared to earlier stages of disease (p=0.024). LM had also shown a decreased expression of Fas (p=0.016). Tumors with low FasL expression upregulate more often their Fas expression (p = 0.028). No correlation could be established regarding the patients survival. CONCLUSIONS: Low expression of Fas and high expression of FasL are more often in colon tumor stage D and in liver metastasis; these imply tumor aggression, resistance against apoptosis, and could be held as negative prognostic factors.
Authors: C Belluco; G Esposito; R Bertorelle; R Alaggio; L Giacomelli; L C Bianchi; D Nitti; M Lise Journal: Eur J Surg Oncol Date: 2002-03 Impact factor: 4.424
Authors: Wolfram V Bernstorff; Jonathan N Glickman; Robert D Odze; Francis A Farraye; Hong G Joo; Peter S Goedegebuure; Timothy J Eberlein Journal: Cancer Date: 2002-05-15 Impact factor: 6.860
Authors: Gero Kramer; Hamdiye Erdal; Helena J M M Mertens; Marius Nap; Julian Mauermann; Georg Steiner; Michael Marberger; Kenneth Bivén; Maria C Shoshan; Stig Linder Journal: Cancer Res Date: 2004-03-01 Impact factor: 12.701
Authors: P Korkolopoulou; A A Saetta; G Levidou; F Gigelou; A Lazaris; I Thymara; M Scliri; K Bousboukea; N V Michalopoulos; N Apostolikas; A Konstantinidou; M Tzivras; E Patsouris Journal: Histopathology Date: 2007-06-08 Impact factor: 5.087
Authors: Janet K Horton; Sharareh Siamakpour-Reihani; Chen-Ting Lee; Ying Zhou; Wei Chen; Joseph Geradts; Diane R Fels; Peter Hoang; Kathleen A Ashcraft; Jeff Groth; Hsiu-Ni Kung; Mark W Dewhirst; Jen-Tsan A Chi Journal: Radiat Res Date: 2015-10-21 Impact factor: 2.841
Authors: Charalabos Pothoulakis; Monica Torre-Rojas; Marco A Duran-Padilla; Jonathan Gevorkian; Odysseas Zoras; Emmanuel Chrysos; George Chalkiadakis; Stavroula Baritaki Journal: Int J Cancer Date: 2017-10-12 Impact factor: 7.316
Authors: M E Peter; A Hadji; A E Murmann; S Brockway; W Putzbach; A Pattanayak; P Ceppi Journal: Cell Death Differ Date: 2015-02-06 Impact factor: 15.828
Authors: Shruti Sharma; Antonio Carmona; Agnieszka Skowronek; Fangyan Yu; Mark O Collins; Sindhu Naik; Claire M Murzeau; Pei-Li Tseng; Kai S Erdmann Journal: Nat Commun Date: 2019-07-15 Impact factor: 14.919
Authors: Ercan Cacan; Alexander M Spring; Anita Kumari; Susanna F Greer; Charlie Garnett-Benson Journal: Int J Mol Sci Date: 2015-12-21 Impact factor: 5.923